Related references
Note: Only part of the references are listed.Acquired resistance to rituximeb is associated with chemotherapy resistance resulting from decreased Bax and Bak expression
Scott H. Olejniczak et al.
CLINICAL CANCER RESEARCH (2008)
Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2008)
In vivo targeting of human neutralizing antibodies against CD55 and CD59 to lymphoma cells increases the antitumor activity of rituximab
Paolo Macor et al.
CANCER RESEARCH (2007)
Mechanisms of killing by anti-CD20 monoclonal antibodies
Martin J. Glennie et al.
MOLECULAR IMMUNOLOGY (2007)
Epigenetic regulation of CD20 protein expression in a novel B-Cell lymphoma cell line, RRBL1, established from a patient treated repeatedly with rituximab-containing chemotherapy
Akihiro Tomita et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2007)
Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma:: An East German Study Group hematology and oncology study
Michael Herold et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
'Rituximab-induced inhibition of antiapoptotic cell survival pathways: implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions'
B. Bonavida
ONCOGENE (2007)
CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: Preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma
Raymond I. Cruz et al.
LEUKEMIA & LYMPHOMA (2007)
Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas:: results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG)
Roswitha Forstpointner et al.
BLOOD (2006)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Establishment of a myeloid leukemia cell line, TRL-01, with MLL-ENL fusion gene
Manabu Ninomiya et al.
CANCER GENETICS AND CYTOGENETICS (2006)
Histone deacetylase 3 (HDAC3) is recruited to target promoters by PML-RARα as a component of the N-CoR co-repressor complex to repress transcription in vivo
Akihide Atsumi et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Analysis of changes in CD20, CD55, and CD59 expression on established rituximab-resistant B-lymphoma cell lines
K Takei et al.
LEUKEMIA RESEARCH (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Monoclonal antibody therapy for B-cell malignancies
Bruce D. Cheson
SEMINARS IN ONCOLOGY (2006)
Epigenetic therapy of cancer: past, present and future
CB Yoo et al.
NATURE REVIEWS DRUG DISCOVERY (2006)
Blockade of bulky lymphoma-associated CD55 expression by RNA interference overcomes resistance to complement-dependent cytotoxicity with rituximab
Y Terui et al.
CANCER SCIENCE (2006)
Comparing antibody and small-molecule therapies for cancer
Kohzoh Imai et al.
NATURE REVIEWS CANCER (2006)
The absence of CD20 messenger RNA in recurrent cutaneous B-cell lymphoma following rituximab therapy
YB Rawal et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2005)
Epigenetics in human disease and prospects for epigenetic therapy
G Egger et al.
NATURE (2004)
Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia
I Jilani et al.
BLOOD (2003)
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
MR Smith
ONCOGENE (2003)
CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma:: a new case report and review of the literature
T Alvaro-Naranjo et al.
ANNALS OF HEMATOLOGY (2003)
Fusion protein of retinoic acid receptor α with promyelocytic leukemia protein or promyelocytic leukemia zinc finger protein recruits N-CoR-TBLR1 corepressor complex to repress transcription in vivo
A Tomita et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Cutaneous B-cell lymphoma with loss of CD20 immunoreactivity after rituximab therapy
LE Clarke et al.
JOURNAL OF CUTANEOUS PATHOLOGY (2003)
Loss of CD20 expression in relapsed lymphomas after rituximab therapy
JH Haidar et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2003)
Apoptotic-regulatory and complement-protecting protein expression in chronic lymphocytic leukemia: Relationship to in vivo rituximab resistance
R Bannerji et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Incidence and nature of CD20-negative relapses following rituximab therapy in aggressive B-cell non-Hodgkin's lymphoma: a retrospective review
GA Kennedy et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study
T Igarashi et al.
ANNALS OF ONCOLOGY (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Lymphoplasmacytic lymphoma with monoclonal gammopathy-related pseudo-Gaucher cell infiltration in bone marrow and spleen - Diagnostic and therapeutic dilemmas
T Robak et al.
LEUKEMIA & LYMPHOMA (2002)
Recurrent B-cell neoplasms after rituximab therapy: An immunophenotypic and genotypic study
PG Chu et al.
LEUKEMIA & LYMPHOMA (2002)
CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy
WT Massengale et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2002)
CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59
J Golay et al.
BLOOD (2001)
Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies
SP Treon et al.
JOURNAL OF IMMUNOTHERAPY (2001)
Share Paper
